Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration

International Journal of Antimicrobial Agents

Volumn 45, Issue 1, 2015, Pages 41-45

  Jamal, Janattul Ain ^a,e   Mat Nor, Mohd Basri ^b   Mohamad Nor, Fariz Safhan ^c   Udy, Andrew A ^d   Wallis, Steven C ^a   Lipman, Jeffrey ^a,e   Roberts, Jason A ^a,e  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA   (Malaysia)

^c Pharmacology Department Kulliyyah of Dentistry UIAM   (Malaysia)

^d ALFRED HOSPITAL   (Australia)

^e ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Continuous infusion; CVVH; Intensive care; Meropenem

Indexed keywords

MEROPENEM; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; CLINICAL ARTICLE; CONTINUOUS HEMOFILTRATION; CONTINUOUS INFUSION; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; FEMALE; HUMAN; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; ADOLESCENT; AGED; CHEMISTRY; CRITICAL ILLNESS; HEMOFILTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PLASMA; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; FEMALE; HEMOFILTRATION; HUMANS; MALE; MIDDLE AGED; PLASMA; PROSPECTIVE STUDIES; THIENAMYCINS; YOUNG ADULT;

EID: 84920482910     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.09.009     Document Type: Article

References (30)

1. R.P. Dellinger, M.M. Levy, A. Rhodes, D. Annane, H. Gerlach, and S.M. Opal Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012 Crit Care Med 41 2013 580 637
2. B.J. Angus, M.D. Smith, Y. Suputtamongkol, H. Mattie, A.L. Walsh, and V. Wuthiekanun Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis Br J Clin Pharmacol 50 2000 184 191
3. S.L. Buijk, I.C. Gyssens, J.W. Mouton, A. Van Vliet, H.A. Verbrugh, and H.A. Bruining Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections J Antimicrob Chemother 49 2002 121 128
4. T.P Lodise Jr., B. Lomaestro, and G.L. Drusano Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy Clin Infect Dis 44 2007 357 363
5. A.A. Udy, J.A. Roberts, and J. Lipman Clinical implications of antibiotic pharmacokinetic principles in the critically ill Intensive Care Med 39 2013 2070 2082
6. C. Buck, N. Bertram, T. Ackermann, T. Sauerbruch, H. Derendorf, and W.D. Paar Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion Int J Antimicrob Agents 25 2005 62 67
7. C. Li, J.L. Kuti, C.H. Nightingale, D.L. Mansfield, A. Dana, and D.P. Nicolau Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection J Antimicrob Chemother 56 2005 388 395
8. J.A. Roberts, M.S. Roberts, T.A. Robertson, A.J. Dalley, and J. Lipman Piperacillin penetration into tissue of critically ill patients with sepsis - bolus versus continuous administration? Crit Care Med 37 2009 926 933
9. J. Langgartner, N. Lehn, T. Gluck, H. Herzig, and F. Kees Comparison of the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion Chemotherapy 53 2007 370 377
10. J. De Waele, M. Carlier, E. Hoste, P. Depuydt, J. Decruyenaere, and S.C. Wallis Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis Minerva Anestesiol 2014 [Epub ahead of print]
11. G. Choi, C.D. Gomersall, Q. Tian, G.M. Joynt, R. Freebairn, and J. Lipman Principles of antibacterial dosing in continuous renal replacement therapy Crit Care Med 37 2009 2268 2282
12. L. Seyler, F. Cotton, F.S. Taccone, D. De Backer, P. Macours, and J.L. Vincent Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy Crit Care 15 2011 R137
13. US Food and Drug Administration. Guidance for industry: bioanalytical method validation 2001 FDA http://www.fda.gov [accessed 30.04.14]
14. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameter. Version 3.1 2013 http://www.eucast.org [accessed 30.04.14]
15. C. Li, X. Du, J.L. Kuti, and D.P. Nicolau Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections Antimicrob Agents Chemother 51 2007 1725 1730
16. F.S. Taccone, F. Cotton, S. Roisin, J.L. Vincent, and F. Jacobs Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock Antimicrob Agents Chemother 56 2012 2129 2131
17. J. Langgartner, A. Vasold, T. Gluck, M. Reng, and F. Kees Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy Intensive Care Med 34 2008 1091 1096
18. C. Robatel, L.A. Decosterd, J. Biollaz, P. Eckert, M.D. Schaller, and T. Buclin Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients J Clin Pharmacol 43 2003 1329 1340
19. T.F. Ververs, A. van Dijk, S.A. Vinks, P.J. Blankestijn, J.F. Savelkoul, and J. Meulenbelt Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration Crit Care Med 28 2000 3412 3416
20. M. Valtonen, E. Tiula, J.T. Backman, and P.J. Neuvonen Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure J Antimicrob Chemother 45 2000 701 704
21. L.J. Giles, A.C. Jennings, A.H. Thomson, G. Creed, R.J. Beale, and A. McLuckie Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration Crit Care Med 28 2000 632 637
22. I. Bilgrami, J.A. Roberts, S.C. Wallis, J. Thomas, J. Davis, and S. Fowler Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration Antimicrob Agents Chemother 54 2010 2974 2978
23. I. Tegeder, F. Neumann, F. Bremer, K. Brune, J. Lotsch, and G. Geisslinger Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration Clin Pharmacol Ther 65 1999 50 57
24. A. Isla, J. Maynar, J.A. Sánchez-Izquierdo, A.R. Gascón, A. Arzuaga, and E. Corral Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients J Clin Pharmacol 45 2005 1294 1304
25. M.M. Meyer, M.Y. Munar, S.J. Kohlhepp, and R.E. Bryant Meropenem pharmacokinetics in a patient with multiorgan failure from meningococcemia undergoing continuous venovenous hemodiafiltration Am J Kidney Dis 33 1999 790 795
26. A. Arzuaga, J. Maynar, A.R. Gascón, A. Isla, E. Corral, and F. Fonseca Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration J Clin Pharmacol 45 2005 168 176
27. P. Deurenberg, M. Deurenberg-Yap, and S. Guricci Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship Obes Rev 3 2002 141 146
28. F. Thalhammer, P. Schenk, H. Burgmann, I. El Menyawi, U.M. Hollenstein, and A.R. Rosenkranz Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration Antimicrob Agents Chemother 42 1998 2417 2420
29. W.A. Krueger, G. Neeser, H. Schuster, T.H. Schroeder, E. Hoffmann, and A. Heininger Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration Chemotherapy 49 2003 280 286
30. J.A. Jamal, A.A. Udy, J. Lipman, and J.A. Roberts The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens Crit Care Med 42 2014 1640 1650